Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | The evolving treatment of MF, PV, and ET: aiming for clonal elimination

Srdan Verstovsek • 28 Sep 2022

SOHO 2022

Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses unanswered questions and the evolving treatment of myelofibrosis (MF), essential thrombocythemia (ET), and polycythemia vera (PV), highlighting the importance of aiming for clonal elimination rather than symptom control. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

An update on the use of navtemadlin in myelofibrosis

Srdan Verstovsek • 7 Dec 2022

Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis

Srdan Verstovsek • 7 Dec 2022

FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement

Srdan Verstovsek • 7 Dec 2022

Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera

Srdan Verstovsek • 7 Dec 2022

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024